EVOLVA HOLDING SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.942 CHF | -5.80% |
|
-10.29% | +30.83% |
| Apr. 15 | Evolva Shareholders Pass Resolutions to Revoke Liquidation, Delisting | MT |
| Mar. 26 | Evolva Secures Temporary Exemption from Listing Rules Amid Liquidation | MT |
| Sales 2022 | 15.54M 17.06M | Sales 2023 | 4.16M 4.56M | Capitalization | 4.9M 5.38M |
|---|---|---|---|---|---|
| Net income 2022 | -43M -47.2M | Net income 2023 | -101M -111M | EV / Sales 2022 | 6.5 x |
| Net Debt 2022 | 9.91M 10.88M | Net cash position 2023 | 5.84M 6.41M | EV / Sales 2023 | -0.23 x |
| P/E ratio 2022 |
-2.02
x | P/E ratio 2023 |
-0.05
x | Employees | 49 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evolva Holding SA
More recommendations
More press releases
More news
| 1 day | -5.80% | ||
| 1 week | -10.29% | ||
| Current month | -6.73% | ||
| 1 month | +4.90% | ||
| 3 months | +38.12% | ||
| 6 months | -69.11% | ||
| Current year | +30.83% |
1 week
0.90
1.07
1 month
0.811.08
Current year
0.621.09
1 year
0.6219.00
3 years
0.6250.75
5 years
0.6293.50
10 years
0.62465.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 22-02-07 | |
Gerhard Lobmaier
COO | Chief Operating Officer | 55 | 20-12-31 |
Astrid Schäfer
CTO | Chief Tech/Sci/R&D Officer | 51 | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 60 | 20-04-14 | |
Beat In-Albon
BRD | Director/Board Member | 72 | 20-04-14 |
Andreas Pfluger
BRD | Director/Board Member | 64 | 22-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.942 | -5.80% | 621 |
| 24-04-18 | 1 | +6.16% | 19,556 |
| 24-04-17 | 0.942 | 0.00% | 1,538 |
| 24-04-16 | 0.942 | -6.73% | 37,500 |
| 24-04-15 | 1.01 | -3.81% | 80,288 |
Delayed Quote Swiss Exchange, April 19, 2024 at 11:30 am EDT
More quotes
Evolva Holding SA (Evolva) is a Switzerland-based biotechnology company reseaching, developing and commerzializing nature-based ingrendients. The activity of the Company is divided into two segments: technololgy platforms - combines biology with technology to produce nature-based ingredients; technology servises- provides tailored services to clients across industries. The Company is focused on developing and increase the yield and efficiency of the production of various ingredients.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +30.83% | 7.91M | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- EVE Stock
